Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 3/20 | 1.00 |
| ▸ | MET | P08581 | 1/20 | 1.00 |
| ▸ | FGFR2 | P21802 | 1/20 | 1.00 |
| ▸ | FGFR3 | P22607 | 1/20 | 1.00 |
| ▸ | AXL | P30530 | 1/20 | 1.00 |
| ▸ | AKT2 | P31751 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 2/20 | 0.40 |
| ▸ | FYN | P06241 | 2/20 | 0.40 |
| ▸ | YES1 | P07947 | 2/20 | 0.40 |
| ▸ | SRC | P12931 | 2/20 | 0.40 |
| ▸ | KDR | P35968 | 2/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.39 |
| ▸ | FLT3 | P36888 | 1/20 | 0.39 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.39 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.39 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.39 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.39 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.39 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.39 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29360864 | 1.00 | FGFR1 (1.00) | FGFR1METFGFR2FGFR3AXL | |
| SCHEMBL259823 | 1.00 | FGFR1 (1.00) | FGFR1METFGFR2FGFR3AXL | |
| SCHEMBL20412333 | 1.00 | FGFR1 (1.00) | FGFR1METFGFR2FGFR3AXL | |
| Hydrochloric Acid SCHEMBL30297725 | 0.99 | FGFR1 (0.98) | FGFR1METFGFR2FGFR3AXL | |
| Hydrochloric Acid SCHEMBL261396 | 0.99 | FGFR1 (0.98) | FGFR1METFGFR2FGFR3AXL | |
| Hydrochloric Acid SCHEMBL17782003 | 0.99 | FGFR1 (0.98) | FGFR1METFGFR2FGFR3AXL | |
| SCHEMBL16359717 | 0.94 | FGFR1 (0.89) | FGFR1METFGFR2FGFR3AXL | |
| SCHEMBL16359718 | 0.94 | FGFR1 (0.89) | FGFR1METFGFR2FGFR3AXL | |
| SCHEMBL1225165 | 0.93 | FGFR1 (0.86) | FGFR1METFGFR2FGFR3AXL | |
| SCHEMBL1225163 | 0.93 | FGFR1 (0.86) | FGFR1METFGFR2FGFR3AXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10245270-B2 | Salt of 3-[(3-{[4-(4-morpholinylmethyl)-1H-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1H-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione, its preparation, and formulations containing it | LES LABORATOIRES SERVIER (FR) | 2019-04-02 | — | — | US | claimed |
| US-20180207171-A1 | SALT OF 3-[(3-{[4-(4-MORPHOLINYLMETHYL)-1H-PYRROL-2-YL]METHYLENE}-2-OXO-2,3-DIHYDRO-1H-INDOL-5-YL)METHYL]-1,3-THIAZOLIDINE-2,4-DIONE, ITS PREPARATION, AND FORMULATIONS CONTAINING IT | LES LABORATOIRES SERVIER (FR) | 2018-07-26 | — | — | US | claimed |
| US-9925195-B2 | Salt of 3-[(3-{[4-(4-morpholinylmethyl)-1H-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1H-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione, its preparation, and formulations containing I | LES LABORATOIRES SERVIER (FR) | 2018-03-27 | — | — | US | claimed |
| EP-3124025-B1 | COMBINATION BETWEEN 3-[(3-{[4-(4-MORPHOLINYLMETHYL)-1H-PYRROL-2-YL] METHYLENE}-2-OXO-2,3-DIHYDRO-1H-INDOL-5-YL)METHYL]-1,3-THIAZOLIDINE-2,4-DIONE AND AN EGFR TYR-KINASE INHIBITOR | SERVIER LAB (FR) | 2018-02-28 | — | — | EP | claimed |
| EP-3019497-B1 | NOVEL SALT OF 3-[(3-{[4-(4-MORPHOLINYLMETHYL)-1H-PYRROL-2-YL]METHYLENE}-2-OXO-2,3-DIHYDRO-1H-INDOL-5-YL)METHYL]-1,3-THIAZOLIDINE-2,4-DIONE, PREPARATION THEREOF AND FORMULATIONS CONTAINING SAME | SERVIER LAB (FR) | 2017-04-12 | — | — | EP | claimed |
| WO-2017021634-A1 | ASSOCIATION BETWEEN 3-[(3-{[4-(4-MORPHOLINYLMETHYL)-1H-PYRROL-2-YL]METHYLENE}-2-OXO-2,3-DIHYDRO-1H-INDOL-5-YL)METHYL]-1,3-THIAZOLIDINE-2,4-DIONE AND A TYROSINE KINASE INHIBITOR OF THE EGFR | LES LABORATOIRES SERVIER (FR) | 2017-02-09 | — | — | WO | claimed |
| US-20170027952-A1 | ASSOCIATION BETWEEN 3-[(3--2-OXO-2,3-DIHYDRO-1H-INDOL-5-YL)METHYL]-1,3-THIAZOLIDINE-2,4-DIONE AND AN EGFR TYR KINASE INHIBITOR | LES LABORATOIRES SERVIER (FR) | 2017-02-02 | — | — | US | claimed |
| EP-3124025-A1 | COMBINATION BETWEEN 3-[(3-{[4-(4-MORPHOLINYLMETHYL)-1H-PYRROL-2-YL] METHYLENE}-2-OXO-2,3-DIHYDRO-1H-INDOL-5-YL)METHYL]-1,3-THIAZOLIDINE-2,4-DIONE AND AN EGFR TYR-KINASE INHIBITOR | Les Laboratoires Servier (FR) | 2017-02-01 | — | — | EP | claimed |
| US-20160151378-A1 | SALT OF 3-[(3--2-OXO-2,3-DIHYDRO-1H-INDOL-5-YL)METHYL]-1,3-THIAZOLIDINE-2,4-DIONE, ITS PREPARATION, AND FORMULATIONS CONTAINING I | LES LABORATOIRES SERVIER (FR) | 2016-06-02 | — | — | US | claimed |
| US-8653073-B2 | Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2014-02-18 | — | — | US | claimed |
| US-20130331380-A1 | DIHYDROINDOLONE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2013-12-12 | — | — | US | claimed |
| US-8541412-B2 | Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2013-09-24 | — | — | US | claimed |
| EP-2281822-B1 | New dihydroindolone derivatives, method of preparing same and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2013-01-16 | — | — | EP | claimed |
| US-8133889-B2 | Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2012-03-13 | — | — | US | claimed |
| US-20120046287-A1 | Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2012-02-23 | — | — | US | claimed |
| WO-2011015728-A1 | NOVEL DIHYDROINDOLONE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | LES LABORATOIRES SERVIER (FR) | 2011-02-10 | — | — | WO | claimed |
| US-20110034460-A1 | Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2011-02-10 | — | — | US | claimed |
| EP-2281822-A1 | New dihydroindolone derivatives, method of preparing same and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2011-02-09 | — | — | EP | claimed |
| US-20250241915-A1 | COMPOUNDS FOR THE TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS | PFIZER INC. (US) | 2025-07-31 | — | — | US | disclosed |
| EP-2281822-A1 | New dihydroindolone derivatives, method of preparing same and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2011-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250241915-A1 | COMPOUNDS FOR THE TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS | BRAF, NRAS, RAF1 | FGFR1 114/4885MET 238/4885FGFR2 297/4885 |
| US-20160151378-A1 | SALT OF 3-[(3--2-OXO-2,3-DIHYDRO-1H-INDOL-5-YL)METHYL]-1,3-THIAZOLIDINE-2,4-DIONE, ITS PREPARATION, AND FORMULATIONS CONTAINING I | DHPS, SLC5A11, INMT | FGFR1 570/4885MET 608/4885FGFR2 546/4885 |
| US-20130331380-A1 | DIHYDROINDOLONE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CYP11B1, SDHA, CYP11B2 | FGFR1 875/4885MET 2084/4885FGFR2 2322/4885 |
| US-20170027952-A1 | ASSOCIATION BETWEEN 3-[(3--2-OXO-2,3-DIHYDRO-1H-INDOL-5-YL)METHYL]-1,3-THIAZOLIDINE-2,4-DIONE AND AN EGFR TYR KINASE INHIBITOR | EGFR, ERBB2, ERBB4 | FGFR1 8/4885MET 6/4885FGFR2 15/4885 |
| US-20120046287-A1 | Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them | CYP11B1, SDHA, CYP11B2 | FGFR1 875/4885MET 2084/4885FGFR2 2322/4885 |
| US-10245270-B2 | Salt of 3-[(3-{[4-(4-morpholinylmethyl)-1H-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1H-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione, its preparation, and formulations containing it | DHPS, SLC5A11, TPMT | FGFR1 1166/4885MET 345/4885FGFR2 1039/4885 |
| US-20180207171-A1 | SALT OF 3-[(3-{[4-(4-MORPHOLINYLMETHYL)-1H-PYRROL-2-YL]METHYLENE}-2-OXO-2,3-DIHYDRO-1H-INDOL-5-YL)METHYL]-1,3-THIAZOLIDINE-2,4-DIONE, ITS PREPARATION, AND FORMULATIONS CONTAINING IT | DHPS, SLC5A11, TPMT | FGFR1 1093/4885MET 341/4885FGFR2 880/4885 |
| US-20110034460-A1 | Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them | CYP11B1, SDHA, CYP11B2 | FGFR1 875/4885MET 2084/4885FGFR2 2322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.